Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP): Price and Financial Metrics


Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP)

Today's Latest Price: $78.28 USD

1.39 (-1.74%)

Updated Sep 29 2:51pm

Add HZNP to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

HZNP Stock Summary

  • HZNP has a higher market value than 89.15% of US stocks; more precisely, its current market capitalization is $16,448,697,758.
  • The price/operating cash flow metric for Horizon Therapeutics Public Ltd Co is higher than 93.65% of stocks in our set with a positive cash flow.
  • HZNP's price/sales ratio is 10.84; that's higher than the P/S ratio of 87.5% of US stocks.
  • Stocks that are quantitatively similar to HZNP, based on their financial statements, market capitalization, and price volatility, are EXAS, AYX, AKAM, NTRA, and BL.
  • Visit HZNP's SEC page to see the company's official filings. To visit the company's web site, go to www.horizontherapeutics.com.
HZNP Daily Price Range
HZNP 52-Week Price Range

HZNP Stock Price Chart Technical Analysis Charts


HZNP Price/Volume Stats

Current price $78.28 52-week high $82.60
Prev. close $79.67 52-week low $23.81
Day low $78.12 Volume 1,112,956
Day high $80.01 Avg. volume 2,227,837
50-day MA $71.67 Dividend yield N/A
200-day MA $47.73 Market Cap 16.16B

Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP) Company Bio


Horizon Pharma plc engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company was founded in 2005 and is based in Dublin, Ireland.

HZNP Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$78.28$47.76 -40%

We started the process of determining a valid price forecast for Horizon Therapeutics Public Ltd Co with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Horizon Therapeutics Public Ltd Co ranked in the 33th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 39.67%. The most interesting components of our discounted cash flow analysis for Horizon Therapeutics Public Ltd Co ended up being:

  • The compound growth rate in the free cash flow of Horizon Therapeutics Public Ltd Co over the past 5.44 years is 0.45%; that's better than 75.06% of cash flow producing equities in the Healthcare sector, where it is classified.
  • The business' balance sheet suggests that 7% of the company's capital is sourced from debt; this is greater than just 17.65% of the free cash flow producing stocks we're observing.
  • Horizon Therapeutics Public Ltd Co's effective tax rate, as measured by taxes paid relative to net income, is at 115 -- greater than 97.73% of US stocks with positive free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-41%
1%-41%
2%-40%
3%-39%
4%-39%
5%-38%

EDAP, GSK, OSMT, PRGO, and MD can be thought of as valuation peers to HZNP, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


HZNP Latest News Stream


Event/Time News Detail
Loading, please wait...

HZNP Latest Social Stream


Loading social stream, please wait...

View Full HZNP Social Stream

Latest HZNP News From Around the Web

Below are the latest news stories about Horizon Therapeutics Public Ltd Co that investors may wish to consider to help them evaluate HZNP as an investment opportunity.

Horizon Therapeutics Stock Hits Record High As Sales Of Key Drug Top Views

Horizon Therapeutics continues to beat expectations for sales of its new drug to treat a rare disease, Tepezza, just seven months after the product launch, powering HZNP stock to new highs.

Yahoo | September 23, 2020

The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPO

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than...

Benzinga | September 16, 2020

MIRROR Open-Label Trial Data Published in Journal of Rheumatology Show 79 Percent of Patients Achieved a Complete Response Using KRYSTEXXA® (pegloticase injection) with Methotrexate

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of the complete dataset on the primary endpoint from its Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA (MIRROR) open-label trial in the Journal of Rheumatology [https://doi.org/10.3899/jrheum.200460]. Horizon’s MIRROR clinical program includes the completed multi-center, open-label trial as well as an ongoing randomized controlled trial (RCT). The tri

Business Wire | September 16, 2020

Horizon Therapeutics Is A Buy

Horizon Therapeutics jumped Tuesday after a huge gain Monday. Cleared 79.03 traditional buy point intraday, probably could have bought at 77.46 s-term high and perhaps even earlier with a downward sloping line. RS line at new high. Second straight gain in above-avg volume.

Yahoo | September 15, 2020

Sangamo Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Threshold

When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. This proprietary rating identifies technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of other stocks on the major indexes. Over 100 years of market history shows that the best stocks tend to have an 80 or higher RS Rating as they begin their biggest climbs.

Yahoo | September 15, 2020

Read More 'HZNP' Stories Here

HZNP Price Returns

1-mo 8.06%
3-mo 41.73%
6-mo 145.78%
1-year 187.48%
3-year 517.35%
5-year 284.48%
YTD 116.24%
2019 85.26%
2018 33.84%
2017 -9.77%
2016 -25.33%
2015 68.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.726 seconds.